Results 91 to 100 of about 280,456 (250)

Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide [PDF]

, 2015
Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C).
Alonso, R., AVERNA, Maurizio, Roeters Van Lennep, J.   +2 more
core   +1 more source

Efficient Scaling up EV‐AAVs Production via Cellular Nanoporation for Familial Hypercholesterolaemia Therapy

Journal of Extracellular Vesicles, Volume 14, Issue 11, November 2025.
ABSTRACT Adeno‐associated virus (AAV)–mediated gene therapies face critical clinical limitations, including immune‐mediated neutralization by pre‐existing antibodies and dose‐dependent hepatotoxicity. Extracellular vesicle‐encapsulated AAVs (EV‐AAVs) offer a promising solution by shielding AAVs from antibody recognition, yet existing production methods
Yuting Yan, Yi You, Shuhong Ma, Hui Yi, Guangduo Chen, Jie Ni, Changyan Chen, Wenyu Ke, Lingying Li, Rui Bai, Yuqing Ran, Wenjing Lu, Min Zhu, Yongshuai Zhang, Jing Dai, Man Qi, Feng Lan, Andrew S. Lee, Ran Zhang, Xujie Liu, Zhaoyang Chen   +20 more
wiley   +1 more source

Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy.

Journal of Lipid Research, 1994
To determine the acute and long-term effects of low density lipoprotein (LDL) reduction on cholesterol biosynthesis, we studied changes in the cholesterol precursors mevalonic acid (MVA) and lathosterol in patients with heterozygous familial ...
M Pfohl, R P Naoumova, C Klass, W Knisel, B Jakober, T Risler, G R Thompson   +6 more
doaj   +1 more source

Comparison of Model‐Predicted and Observed Evinacumab Pharmacokinetics and Efficacy in Children Aged < 5 Years With Homozygous Familial Hypercholesterolemia

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1835-1847, November 2025.
ABSTRACT Evinacumab, an angiopoietin‐like 3 inhibitor, significantly reduces low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). Herein, we report pharmacokinetic and efficacy analyses of evinacumab in < 5‐year‐old patients with HoFH.
Sébastien Bihorel, Robert Dingman, Jeanne Mendell, Katy C. Norman, Richard T. George, Xue‐Qiao Zhao, Robert Pordy, Daniel Garcia, Wendy S. Putnam, Geetha Raghuveer, Brian W. McCrindle, Elena Fornari, Ivo Baric, Shubha Srinivasan, Melissa Diamond, Eliot A. Brinton, John D. Davis, A. Thomas DiCioccio, Lutz Harnisch   +18 more
wiley   +1 more source

Lipid-Apheresis Improves Microcirculation of the Upper Limbs [PDF]

, 2012
Mit Lipid-Apherese (LA) ist es möglich die Mikrozirkulation zu verbessern. Wir haben die Mikrozirkulation der oberen Extremitäten von 22 Patienten vor und nach wöchentlicher LA untersucht.
Rossenbach, Jannik
core  

Impact of platelet transfusions on plasma proteomes in controlled endotoxemia and in hemato‐oncological patients

Transfusion, Volume 65, Issue 10, Page 1825-1838, October 2025.
Abstract Background Inflammation is a hallmark of patients that receive platelet transfusions, including critically ill and hemato‐oncological patients. Platelet transfusions have been suggested to exacerbate inflammatory conditions, resulting in transfusion‐related complications.
Eva R. Smit, Isabella Viegen, Pieter F. van der Meer, Stefan F. van Wonderen, Floor L. F. van Baarle, Paula F. Ypma, Jean‐Louis H. Kerkhoffs, Jan Voorberg, Alexander P. J. Vlaar, Anna L. Peters, Maartje van den Biggelaar, Diana Muñoz Sandoval   +11 more
wiley   +1 more source

Lipoprotein lipase regulates hematopoietic stem progenitor cell maintenance through DHA supply. [PDF]

, 2018
Lipoprotein lipase (LPL) mediates hydrolysis of triglycerides (TGs) to supply free fatty acids (FFAs) to tissues. Here, we show that LPL activity is also required for hematopoietic stem progenitor cell (HSPC) maintenance.
Han, Tianxu, Kim, Jungsu, Klemke, Richard L, Liu, Chao, Miller, Yury I, Rana, Tariq M, Remaley, Alan T, Stachura, David L, Traver, David, Vaisman, Boris L, Wang, Huawei   +10 more
core   +2 more sources

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Intensive Combination LDL-Lowering Therapy in a Patient With Homozygous Familial Hypercholesterolemia

JACC: Case Reports
We present a young boy with a diagnosis of homozygous familial hypercholesterolemia who presented with statin and ezetimibe resistance. The patient received lipoprotein apheresis at 6 years of age.
Hayato Tada, MD, Hirofumi Okada, MD, Masa-aki Kawashiri, MD, Masayuki Takamura, MD   +3 more
doaj   +1 more source

Three patients with homozygous familial hypercholesterolemia: Genomic sequencing and kindred analysis. [PDF]

, 2019
BackgroundHomozygous Familial Hypercholesterolemia (HoFH) is an inherited recessive condition associated with extremely high levels of low-density lipoprotein (LDL) cholesterol in affected individuals.
Balamir, Melek, Chu, Catherine, Gonzaludo, Nina, Grenville, Zoe, Kane, John P, Kwok, Pui-Yan, Lao, Richard, Levy-Sakin, Michal, Ma, Walfred, Mak, Angel CY, Malloy, Mary J, Poon, Annie, Pullinger, Clive R, Vaka, Dedeepya, Wong, Karen HY, Wong, Nicolas   +15 more
core   +1 more source